TO: EZIZ Users

FROM: CDPH

SUBJECT: CDC Influenza Webinar

DATE: 1/16/19

2018-2019 Influenza Season and Recommendations for Clinicians Overview

Influenza activity in the United States is increasing and is expected to continue at elevated levels for several more weeks. Influenza A(H1N1)pdm09 viruses have been most common this season; influenza A(H3N2) and influenza B viruses are also circulating. In the southeastern part of the country, influenza A(H3N2) viruses have been most commonly reported this season. Annual influenza vaccination is recommended for all people 6 months and older and is the best way to prevent influenza and its potentially serious complications. Available evidence consistently indicates that antiviral treatment initiated as early as possible can be a useful second line of defense to treat influenza illness when indicated and can reduce severe outcomes of influenza.

During this COCA Call, clinicians will learn about 2018 –2019 influenza activity and hear an overview of CDC's recommendations for health care providers regarding influenza vaccination and the use of influenza antiviral medications for the 2018-2019 influenza season, including a new antiviral medication approved by the FDA in October 2018. Date: Tuesday, January 29, 2019

Time: 2:00-3:00 P.M. ET

A few minutes before the webinar begins, please click the link below to join the webinar:

https://zoom.us/j/862187873

Or iPhone one-tap:

US: +16468769923,,862187873# or +16699006833,,862187873#

Or Telephone:

US: +1 646 876 9923 or +1 669 900 6833

Webinar ID: 862 187 873

International numbers available here: <u>https://zoom.us/u/afuFnVK9Q</u>

The recordings (audio, slides, and transcript) for this call will be posted on the <u>webpage</u> a week after the COCA Call.

Free <u>Continuing Education (CE)</u> is available for most COCA Calls. Please

see below for instructions on how to receive CE.

Activity Specific Objectives

At the conclusion of this COCA Call, the participant will be able to accomplish the following:

- Summarize the current status of influenza activity in the United States.
- Discuss the circulating influenza strains seen this season and the implications for clinicians.
- Describe antiviral treatment recommendations for patients with influenza

COCA call Objectives

At the conclusion of the session, the participant will be able to accomplish the following:

- 1. Cite background information on the topic covered during the presentation.
- 2. Discuss CDC's role in the topic covered during the presentation.
- 3. Describe the topic's implications for clinicians.
- 4. Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
- 5. Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of health care providers.

Presenters Alicia P. Budd, MPH

Epidemiologist

Influenza Division

National Center for Immunization and Respiratory Diseases

Centers for Disease Control and Prevention

Angela Campbell, MD, MPH

Medical Officer

Influenza Division

National Center for Immunization and Respiratory Diseases

Centers for Disease Control and Prevention

Instructions for Obtaining Continuing Education (CE) To receive continuing education (CE) for WC2922-12919 – (Webcast) Clinician Outreach and Communication Activity (COCA) Calls/Webinars – <u>"2018-2019</u> Influenza Season and Recommendations for Clinicians" – January 29, 2019, please visit <u>TCEO</u> and follow these <u>9 Simple Steps</u> by February 28, 2019.

To receive continuing education (CE) for **WD2922-12919** – Clinician Outreach and Communication Activity (COCA) Calls/Webinars – <u>"2018-2019 Influenza Season</u> and Recommendations for Clinicians" – January 29, 2019, (Web on Demand), please visit <u>TCEO</u> and follow these <u>9 Simple Steps</u> by **March 1, 2021**.

Accreditation Statements

CME: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

The Centers for Disease Control and Prevention designates this live activity for a maximum of **1.0** AMA PRA Category 1 Credit[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CNE: The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center's Commission on Accreditation.

This activity provides **1.0** contact hour.

CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU's for this program.

CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES) and/or Master Certified Health Education Specialists (MCHES) to receive up to total **1.0** total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. CDC provider number **98614**.

CPE: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is a designated event for pharmacists to receive) **0.1** CEUs in pharmacy education. The Universal Activity Number is **0387-0000-19-070-L04-P** and enduring **0387-0000-19-070-H04-P** course category.

This activity has been designated as Knowledge-Based.

Once credit is claimed, an unofficial statement of credit is immediately available on TCEOnline. Official credit will be uploaded within 60 days on the NABP/CPE Monitor.

For Certified Public Health Professionals (CPH)

The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1.0 CPH recertification credit for this program.

AAVSB/RACE: This program was reviewed and approved by the AAVSB RACE program for **1.0** hours of continuing education. Participants should be aware that some boards have limitations on the number of hours accepted in certain categories and/or restrictions on certain methods of delivery of continuing education. Please contact the AAVSB RACE program at <u>race@aavsb.org</u> if you have any comments/concerns regarding this program's validity or relevancy to the veterinary profession

DISCLOSURE: In compliance with continuing education requirements, CDC, our planners, our presenters, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters. Planners have reviewed content to ensure there is no bias. The presentation will not include any discussion of the unlabeled use of a product or a product under investigational use. CDC did not accept commercial support for this continuing education activity